Aligos Therapeutics (ALGS) Preferred Stock Liabilities (2019 - 2020)
Aligos Therapeutics' (ALGS) quarterly Preferred Stock Liabilities came in at $14.6 million in Q3 2020, down 85.52% YoY from $100.5 million in Q4 2019, and down 82.11% on a QoQ basis from $81.4 million in Q2 2020.
Aligos Therapeutics (ALGS) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Aligos Therapeutics (ALGS) has 2 years of Preferred Stock Liabilities data on file, last reported at $14.6 million in Q3 2020.
- Quarterly Preferred Stock Liabilities fell 85.52% year-over-year to $14.6 million in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $14.6 million (down 85.52% YoY) and the FY2019 annual result came in at $100.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities declined to $14.6 million in Q3 2020, from $81.4 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $100.7 million in Q4 2019 to a low of $14.6 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 14.56 Mn |
| Jun 30, 2020 | 81.38 Mn |
| Mar 31, 2020 | 81.38 Mn |
| Dec 31, 2019 | 100.70 Mn |
| Sep 30, 2019 | 100.52 Mn |